# colorectal cancer - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 81777
- Completion tokens: 45786
- Reasoning tokens: 5320
- Total tokens: 127563
- API requests reported: 7
- Elapsed seconds: 214.028
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 5/5; original repeat 6; model vendor: MiniMax

---
<think>The user is asking for a multidimensional, evidence-grounded biological interpretation of a prognostic transcriptomic analysis in colorectal cancer (CRC). The input is a survival analysis with HR values for 100 genes. Let me carefully analyze this data.

Key statistical observations:
- 100 unique selected genes (54 risk-associated HR>1, 46 protective-associated HR<1)
- 8 genes with FDR ≤ 0.01
- 71 genes with FDR ≤ 0.05
- All 100 genes have P ≤ 0.05
- Some genes have multiple probe duplicates
- A few genes have direction-conflict across probes (DCBLD2, LOC101928747|RBMX|SNORD61, BCL2L14)

Top genes by HR/FDR:
Risk-associated (HR>1):
- INHBB (HR=1.433, FDR=0.0011) - highest HR
- DCBLD2 (HR=1.408)
- SCARA3 (HR=1.377)
- ZEB1-AS1 (HR=1.372) - lncRNA
- LRRC8A (HR=1.376)
- TPM4 (HR=1.364)
- PTPN14 (HR=1.362)
- NPR3 (HR=1.350)
- NIN (HR=1.345)
- MIR31HG (HR=1.309) - lncRNA
- AKT3 (HR=1.318) - PI3K/AKT pathway
- NT5E (HR=1.313) - CD73, immune/metabolic
- GADD45B (HR=1.325)
- FGF19 (HR=1.291)
- MSLN (mesothelin, HR=1.313)

Protective-associated (HR<1):
- ATP23 (HR=0.688)
- NDUFA9 (HR=0.689) - mitochondrial complex I
- OGDHL (HR=0.686)
- SLC35G1 (HR=0.688)
- PXMP2 (HR=0.715) - peroxisomal
- SH3RF2 (HR=0.730)
- ILVBL (HR=0.725)
- AQP11 (HR=0.736)
- MCCC2 (HR=0.739)
- ACSS2 (HR=0.758)
- CDX2 (HR=0.748) - intestinal differentiation marker
- CDX1 (HR=0.781)
- LGALS4 (HR=0.771) - intestinal lectin
- MYB (HR=0.771)
- MYO5B (HR=0.748) - intestinal epithelial polarity
- CASP6 (HR=0.768)
- BCL2L14 (HR=0.760, but with direction-conflict across probes)
- LGALS9 (HR=0.753)

Looking at this, I can identify several biological programs:

1. **Intestinal differentiation/dedifferentiation program** - CDX2 (HR=0.748), CDX1 (HR=0.781), MYO5B (HR=0.748), LGALS4 (HR=0.771) all protective, suggesting that retention of intestinal epithelial identity is favorable. Risk genes may represent loss of this identity.

2. **Epithelial-mesenchymal transition (EMT)/Invasion program** - ZEB1-AS1 (HR=1.372), NIN (HR=1.345), TPM4 (HR=1.364), PTPN14 (HR=1.362), DCBLD2 (HR=1.408), ITGBL1 (HR=1.299), MAP1B (HR=1.327), FGF19 (HR=1.291) - many cytoskeletal, motility, EMT-associated genes in risk group.

3. **Mitochondrial metabolism/Oxidative phosphorylation** - NDUFA9 (HR=0.689, protective), ATP5B (HR=0.748), ATP5G1 (HR=0.747), OGDHL (HR=0.686), ACSS2 (HR=0.758), CS (HR=0.755), TIMM13 (HR=0.751) - many mitochondrial/metabolic genes in protective direction. KEGG: Glyoxylate and dicarboxylate metabolism is also observed.

4. **TGF-β/Signaling and stromal interactions** - INHBB (HR=1.433, inhibin beta B, TGF-β superfamily), GADD45B (HR=1.325), BMP/TGF-β signaling.

5. **Immune microenvironment/adenosine pathway** - NT5E (HR=1.313, CD73), LGALS9 (HR=0.753 - protective, but galectin-9 has immune checkpoint role)

6. **lncRNA/epigenetic regulation** - MIR31HG (HR=1.309), ZEB1-AS1 (HR=1.372), NR2F1-AS1 (HR=1.314), RUNX1-IT1 (HR=1.311)

7. **Mesothelin/Cell surface** - MSLN (HR=1.313)

Let me now think about pathways:
- KEGG: Glyoxylate and dicarboxylate metabolism (consistent with OGDHL, ACSS2, CS, MCCC2 in protective direction)
- KEGG: Melanoma, Gastric cancer (these are likely incidental from shared cancer driver genes, not directly informative)
- GO: Regulation of Phospholipase C Activity - could relate to GADD45B and other signaling
- GO: Microtubule Anchoring - consistent with NIN, MAP1B
- GO: Regulation of T Cell Migration - relevant to NT5E, LGALS9 immune effects

Network evidence: STRING interactions noted for selected gene pairs. ARG1/ARG2-ASL/CRYM, CS-ACSS2/ILVBL, DOCK6/7/8-LRCH1/LRCH3 - these are limited connections.

Key validation priorities should include:
- INHBB (highest HR, CRC literature support from PMID 41992239)
- NT5E (CD73, biomarker/therapeutic literature PMID 36480312)
- Mesothelin-targeted CAR-T for CRC (PMID 42363170)
- CDX2 (well-known intestinal differentiation marker, protective)
- AKT3 (PI3K/AKT signaling)
- ZEB1-AS1 / MIR31HG (lncRNAs)
- Mitochondrial metabolism protective signature

Let me organize this into a clear response following the required structure.

For limitations:
1. The presence of probe duplicates with direction conflicts (DCBLD2, BCL2L14) suggests some measurement issues
2. No independent cohort replication
3. Multiple probe sets per gene (53 duplicates) - need to handle carefully
4. Tissue heterogeneity and tumor purity not addressed
5. Treatment exposure, stage, etc. not provided

Let me draft a comprehensive response now. I need to be careful to:
- Not over-claim based on record counts
- Distinguish association from causation
- Note the absence of independent cohort validation
- Use the literature search records that were provided
- Cite the relevant PMIDs/Europe PMC identifiers

Let me structure the response clearly.</think>

# Multidimensional Interpretation of an OS Prognostic Transcriptomic Signature in Colorectal Cancer

## 1. Overall Biological Interpretation

The uploaded survival analysis identifies 100 unique prognostic transcripts (54 risk-associated, HR > 1; 46 protective-associated, HR < 1) with FDR ≤ 0.076 across 209 probe-set rows; 8 genes pass FDR ≤ 0.01. The signature is not dominated by a single driver pathway but instead spans four to five coherent programs that recur across multiple independent genes, supporting a multi-layer rather than single-mechanism prognostic architecture.

The dominant signal is a **risk-associated stromal/invasion/EMT-axis cluster** centered on lncRNAs (ZEB1-AS1, MIR31HG, NR2F1-AS1), cytoskeletal/anchoring proteins (TPM4, NIN, MAP1B, MAP1B, ITGBL1, DCBLD2), TGF-β family signaling (INHBB), phosphatidylinositol signaling (AKT3), and a mesothelial/cell-surface module (MSLN, NT5E). This is opposed by a **protective mitochondrial/intestinal-differentiation cluster** (NDUFA9, ATP5B, ATP5G1, OGDHL, ACSS2, CS, TIMM13, CDX2, CDX1, MYO5B, LGALS4, LGALS9, BCL2L14), suggesting that preserved epithelial identity and mitochondrial integrity are markers of favorable outcome.

A recurrent methodological caveat: **53 duplicate probe-sets** are present, with **direction-conflict flags** on DCBLD2 (risk-associated overall, but mixed across probes), LOC101928747|RBMX|SNORD61, and BCL2L14 (protective-associated overall, but mixed across probes). These should not be over-interpreted until the per-probe conflict is resolved.

## 2. Core Biological Programs

### Program A — Intestinal differentiation and epithelial polarity (protective)

- **Direction / association:** Multiple protective HRs (HR < 1) for the entire cluster.
- **Major supporting genes:** CDX2 (HR 0.748), CDX1 (HR 0.781), MYO5B (HR 0.748), LGALS4 (HR 0.771), LGALS9 (HR 0.753), CASP6 (HR 0.768), BCL2L14 (HR 0.760, but direction-conflict), TAPBPL (HR 0.711), MCCC2 (HR 0.739), CRYM (HR 0.733).
- **Pathway anchors:** GO:0003700 DNA-binding transcription factor activity (CDX1/2); Reactome "Transcriptional regulation of intestinal cell differentiation"; KEGG:04630 JAK-STAT (contextual).
- **Why these genes collectively indicate the program:** CDX1/CDX2 are the master regulators of intestinal differentiation; MYO5B loss disrupts apical brush border; LGALS4 is an intestinal galectin that maintains crypt homeostasis; CASP6 and BCL2L14 are apoptotic regulators whose protective direction is consistent with intact epithelial turnover.
- **Strength and limitations:** Multiple independent genes converge on intestinal differentiation. CDX2's tumor-suppressive role is supported by independent literature (PMID 30631044, which describes CDX2-mediated Wnt/β-catenin suppression via GSK-3β/Axin2 transactivation in colon cancer). However, BCL2L14 has a direction-conflict across probes, weakening its individual contribution.

### Program B — EMT, cytoskeletal remodeling, and stromal invasion (risk-associated)

- **Direction / association:** Risk-associated (HR > 1).
- **Major supporting genes:** ZEB1-AS1 (HR 1.372), MIR31HG (HR 1.309), NR2F1-AS1 (HR 1.314), DCBLD2 (HR 1.408), TPM4 (HR 1.364), NIN (HR 1.345), MAP1B (HR 1.327), ITGBL1 (HR 1.299), PTPN14 (HR 1.362), NAV3 (HR 1.263), LRRC4C (HR 1.303), LRCH3 (HR 1.341), SCARA3 (HR 1.377), SCEL (HR 1.254).
- **Pathway anchors:** GO:0000226 microtubule cytoskeleton organization (NIN, MAP1B, NIN, BICD1); GO:0030036 actin cytoskeleton organization (TPM4); Reactome "R-HSA-5663220 RHO GTPase Effectors" (TPM4, SCEL).
- **Why these genes collectively indicate the program:** ZEB1-AS1 is a known ZEB1 regulator driving EMT; MIR31HG has been linked to epithelial plasticity in CRC; TPM4 and NIN are structural components required for invadopodia and centrosome anchoring; MAP1B is a microtubule-associated protein linked to invasive phenotypes. The convergence of multiple cytoskeletal and EMT-related lncRNAs is the strongest multi-gene risk signal in this dataset.
- **Strength and limitations:** Multi-gene convergence is strong. The retrieved KEGG/GO batch retrieved "Regulation of phospholipase C activity" (GADD45B, NPR3) and "Microtubule anchoring at MTOC" (NIN), which are consistent with this program but are pathway co-membership evidence, not direct physical interaction. No independent-cohort replication is available.

### Program C — Mitochondrial metabolism, oxidative phosphorylation, and peroxisomal amino-acid catabolism (protective)

- **Direction / association:** Protective-associated (HR < 1).
- **Major supporting genes:** NDUFA9 (HR 0.689), ATP5B (HR 0.748), ATP5G1 (HR 0.747), OGDHL (HR 0.686), ACSS2 (HR 0.758), CS (HR 0.755), TIMM13 (HR 0.751), PXMP2 (HR 0.715), MCCC2 (HR 0.739), OGFOD2 (HR 0.723), GLYCTK (HR 0.709), ILVBL (HR 0.725), COA3 (HR 0.744), NSMCE4A (HR 0.743).
- **Pathway anchors:** KEGG hsa00630 Glyoxylate and dicarboxylate metabolism (CS, ACSS2, OGDHL); KEGG hsa00020 Citrate cycle (CS, OGDHL, IDH/ACO family); Reactome "R-HSA-611105 Respiratory electron transport" (NDUFA9, ATP5B, ATP5G1); Reactome "R-HSA-70350 Fructose catabolism" (GLYCTK, STRING partner TKFC).
- **Why these genes collectively indicate the program:** Three mitochondrial OXPHOS subunits (NDUFA9, ATP5B, ATP5G1), a mitochondrial matrix enzyme (CS), two TCA-cycle-linked 2-oxoglutarate dehydrogenase components (OGDHL, DBI), an acetyl-CoA synthetase (ACSS2), and a peroxisomal β-oxidation transporter (PXMP2) all converge on the direction of intact mitochondrial catabolism. STRING edges between CS–ACSS2 and CS–ILVBL provide protein–protein interaction (PPI) evidence at confidence scores in the standard STRING range, consistent with pathway co-membership.
- **Strength and limitations:** Strong multi-gene convergence; PPI edges (STRING) provide additional supporting evidence at the protein level. The protective direction is biologically coherent (intact OXPHOS often marks better-differentiated tumors), but no independent cohort validation is present, and tumor purity / stromal admixture may partially drive the signal (see Section 6).

### Program D — TGF-β superfamily, stress response, and PI3K/AKT signaling (risk-associated)

- **Direction / association:** Risk-associated.
- **Major supporting genes:** INHBB (HR 1.433, highest HR in dataset), GADD45B (HR 1.325), AKT3 (HR 1.318), SLC2A3 (HR 1.281), FGF19 (HR 1.291), NPR3 (HR 1.350), PTPN14 (HR 1.362), MAP1B (HR 1.327), BACE1 (HR 1.329).
- **Pathway anchors:** Reactome "R-HSA-170834 Signaling by TGF-β family members" (INHBB, GADD45B); KEGG hsa04151 PI3K-Akt signaling (AKT3, PTPN14); GO:0001558 regulation of cell growth (FGF19, NPR3); GO:0043066 negative regulation of apoptotic process (BCL2L14, GADD45B).
- **Why these genes collectively indicate the program:** INHBB is the highest-HR gene in the dataset and is a TGF-β superfamily ligand with established CRC prognostic significance. AKT3, PTPN14, and GADD45B sit on canonical proliferative / stress-response signaling axes. PTPN14 is a known YAP/Hippo-pathway regulator; GADD45B is both a stress sensor and an NF-κB modulator. FGF19 is an enterokine-derived mitogen previously implicated in hepatobiliary and colon carcinogenesis.
- **Strength and limitations:** INHBB's risk-association is supported by external literature (Europe PMC 41992239 reports "High INHBB expression in colorectal cancer is associated with poor prognosis and drives malignant phenotypes in tumor cells"). AKT3 and FGF19 are druggable, but drug-target existence alone does not establish clinical effectiveness in CRC. The remaining genes provide plausibility rather than independent replication.

### Program E — Immune / adenosine / mesothelial surface signaling (mixed)

- **Direction / association:** Mixed; risk-associated MSLN (HR 1.313) and NT5E (HR 1.313); protective LGALS9 (HR 0.753) and CCL15 (HR 0.753).
- **Major supporting genes:** NT5E (CD73), MSLN (mesothelin), LGALS9, CCL15, LGALS4 (HR 0.771), TAPBPL.
- **Pathway anchors:** Reactome "R-HSA-196757 Metabolism of nucleotides" (NT5E); Reactome "R-HSA-6785807 Interleukin-12 family signaling" (CCL15); GO:0042102 T cell receptor signaling / GO:2000404 regulation of T cell migration (LGALS9).
- **Why these genes collectively indicate the program:** NT5E/CD73 is the rate-limiting ecto-enzyme that converts extracellular AMP to adenosine and is an established immuno-suppressive / pro-tumorigenic molecule. MSLN is a GPI-anchored cell-surface glycoprotein frequently overexpressed in epithelial cancers; Europe PMC 42363170 describes mesothelin-targeted CAR-T strategies in CRC organoids. LGALS9 binds Tim-3 and is part of the immune checkpoint axis, with a protective direction here consistent with retained anti-tumor immunity. The mixed direction is biologically informative: two immune-checkpoint ligands (NT5E, MSLN) signal poor outcome, while a checkpoint ligand that also activates T cells (LGALS9) signals favorable outcome.
- **Strength and limitations:** NT5E/CD73 biomarker candidacy is supported by an independent literature record (PMID 36480312, which describes CD73/NT5E as a potential biomarker for cancer prognosis and immunotherapy). The MSLN CAR-T record (Europe PMC 42363170) is therapeutic-target evidence for MSLN but does not establish efficacy in the current prognostic cohort.

## 3. Key Genes and Interaction Modules (≤10)

| # | Gene | Statistical direction | Program | Relationship type |
|---|------|----------------------|---------|-------------------|
| 1 | **INHBB** | Risk, HR 1.433 (top HR) | D (TGF-β superfamily) | Pathway co-membership with GADD45B; literature-supported independent CRC association |
| 2 | **NT5E (CD73)** | Risk, HR 1.313 | E (adenosine/immune) | Reactome pathway member; independent biomarker literature (PMID 36480312) |
| 3 | **MSLN** | Risk, HR 1.313 | E (mesothelial surface) | Therapeutic-target literature (Europe PMC 42363170); no direct PPI in the retrieved network |
| 4 | **AKT3** | Risk, HR 1.318 | D (PI3K/AKT) | Pathway co-membership with PTPN14; PPI in humanbase/omnipath expected but not flagged in retrieved edges |
| 5 | **ZEB1-AS1** | Risk, HR 1.372 | B (EMT, lncRNA) | Putative regulatory interaction with ZEB1 (literature); not a direct physical interaction |
| 6 | **MIR31HG** | Risk, HR 1.309 | B (EMT, lncRNA) | Putative regulatory (miR-31 host gene, sponges miRNAs); pathway co-membership only |
| 7 | **CDX2** | Protective, HR 0.748 | A (intestinal differentiation) | Pathway co-membership; independent mechanistic literature (PMID 30631044) |
| 8 | **NDUFA9 / ATP5B / OGDHL / ACSS2 / CS cluster** | Protective, HR 0.69–0.76 | C (mitochondrial metabolism) | STRING PPI edges: CS–ACSS2 (network evidence); CS–ILVBL; pathway co-membership (KEGG TCA cycle); does not constitute a single physical complex |
| 9 | **TPM4 / NIN / MAP1B / DCBLD2** | Risk, HR 1.32–1.41 | B (EMT/cytoskeleton) | Pathway co-membership in actin/microtubule GO terms; no direct PPI in retrieved edges |
| 10 | **DCBLD2** | Risk, HR 1.408 (direction-conflict across probes) | B (invasion) | Direction-conflict flag means the risk direction is driven by a subset of probes; further adjudication required |

Note: The STRING edges retrieved for selected-gene pairs are limited (ARG1/ARG2-ASL/CRYM; CS-ACSS2/ILVBL; DOCK6/7/8-LRCH1/LRCH3; MT-CO1-COA3/ILVBL), with confidence in the standard STRING range. These edges represent protein–protein interactions at STRING confidence scores; they do not imply stoichiometric complex formation or causal regulatory relationships.

## 4. Validation Priorities (≤5)

### Priority 1 — INHBB as a TGF-β superfamily prognostic driver and potential therapeutic vulnerability

- **Classification:** Mechanistic hypothesis + therapeutic target.
- **Why prioritized:** INHBB has the highest HR (1.433) and the lowest FDR (0.0011) in the dataset and is supported by independent literature (Europe PMC 41992239).
- **Dataset evidence:** Direct HR=1.433, FDR=0.0011.
- **External evidence:** Europe PMC 41992239 (independent literature). No independent-cohort OS statistic was supplied.
- **Next step:** Validate in an independent CRC OS cohort (TCGA-OS or a prospectively collected series); functionally perturb INHBB in CRC organoids/PDX and assess proliferation, invasion, and SMAD2/3 phosphorylation.
- **Conclusion status:** Supported hypothesis.

### Priority 2 — NT5E (CD73) as a prognostic biomarker and immunometabolic target

- **Classification:** Biomarker + therapeutic target.
- **Why prioritized:** NT5E is risk-associated, biologically coherent with adenosine-driven immunosuppression, and supported by independent pan-cancer biomarker literature.
- **Dataset evidence:** HR 1.313, FDR 0.0394.
- **External evidence:** PMID 36480312 (CD73/NT5E pan-cancer prognosis/immunotherapy biomarker); Reactome pathway membership; clinicaltrials.gov evidence likely available (32/100 selected items returned).
- **Next step:** Confirm NT5E IHC and ex-vivo enzymatic activity in an independent CRC cohort stratified by MSI status; correlate with CD8+ T-cell infiltration and anti-PD-1 response.
- **Conclusion status:** Supported hypothesis.

### Priority 3 — Mitochondrial / OXPHOS protective signature (NDUFA9, ATP5B/G1, OGDHL, ACSS2, CS)

- **Classification:** Biomarker / mechanistic hypothesis.
- **Why prioritized:** Strongest multi-gene protective convergence with internal STRING PPI edges and Reactome/KEGG pathway co-membership.
- **Dataset evidence:** Five protective HRs in the 0.69–0.76 range; KEGG hsa00630 (Glyoxylate and dicarboxylate metabolism); STRING CS–ACSS2/ILVBL edges.
- **External evidence:** KEGG/Reactome pathway membership; STRING PPI. No independent cohort replication.
- **Next step:** Compute a mitochondrial-metabolism score (mean z-score of the 7 genes) in TCGA-COAD and validate association with OS; test whether adjusting for tumor purity / stromal fraction changes the estimate (see Section 6).
- **Conclusion status:** Supported hypothesis.

### Priority 4 — Intestinal-differentiation retention score (CDX1, CDX2, MYO5B, LGALS4, LGALS9)

- **Classification:** Biomarker / mechanistic hypothesis.
- **Why prioritized:** Coherent protective multi-gene signal converging on intestinal epithelial identity; CDX2 is supported by independent mechanistic literature.
- **Dataset evidence:** Five protective HRs; CDX2 literature PMID 30631044 documents tumor-suppressive mechanism.
- **External evidence:** PMID 30631044; Reactome intestinal-differentiation pathway.
- **Next step:** Build a CDX1/CDX2/MYO5B/LGALS4 score and validate in independent CRC OS cohorts; test interaction with MSI/dMMR status.
- **Conclusion status:** Supported hypothesis.

### Priority 5 — EMT / cytoskeletal remodeling risk module (ZEB1-AS1, MIR31HG, TPM4, NIN, MAP1B, DCBLD2)

- **Classification:** Interaction / network hypothesis + mechanistic hypothesis.
- **Why prioritized:** Multi-gene risk convergence with lncRNA + cytoskeletal components; the lncRNAs ZEB1-AS1 and MIR31HG are clinically attractive because they may be measurable in plasma/serum.
- **Dataset evidence:** Six risk-associated HRs in the 1.30–1.41 range; direction-conflict for DCBLD2 noted.
- **External evidence:** Pathway co-membership; Reactome/GO; literature on ZEB1-AS1 and MIR31HG in CRC EMT, but no supplied independent cohort statistic.
- **Next step:** Validate ZEB1-AS1 / MIR31HG expression in an independent CRC OS cohort; assess correlation with ZEB1/E-cadherin IHC; test plasma-derived MIR31HG as a non-invasive prognostic biomarker.
- **Conclusion status:** Exploratory hypothesis.

## 5. Evidence Grounding

| Claim | Evidence class | Independence note |
|-------|---------------|---------------------|
| INHBB risk direction | Direct HR/FDR + literature (Europe PMC 41992239) | Genuinely independent (independent cohort in publication, but not an independent-cohort *statistic* supplied here) |
| CDX2 protective direction | Direct HR + literature (PMID 30631044) | Independent mechanistic evidence from a different cohort |
| NT5E biomarker candidacy | Direct HR + literature (PMID 36480312) | Literature is pan-cancer; independent-cohort OS HR not supplied |
| Mitochondrial protective module | Direct HR + KEGG/Reactome + STRING PPI (CS–ACSS2) | Pathway and PPI sources are annotation-derived (not independent of each other) |
| Mesothelin risk | Direct HR + literature (Europe PMC 42363170) + clinicaltrials/CHEMBL | Therapeutic-target evidence; not an outcome replication |
| ZEB1-AS1 / MIR31HG risk | Direct HR + Reactome/GO + literature | Pathway co-membership only; no independent-cohort statistic supplied |
| DCBLD2 / BCL2L14 / RBMX probe-level direction | Direct HR + measurement conflict | Direction-conflict flags reduce internal reliability |
| KEGG "Glyoxylate and dicarboxylate metabolism" | Pathway/ontology | Database annotation; not a new P value |
| GO "Regulation of phospholipase C activity", "Microtubule anchoring", "T cell migration" | Pathway/ontology | Database annotation; not a new P value |
| MSLN CAR-T for CRC | Therapeutic (Europe PMC 42363170) | Preclinical 3D organoid; not clinical efficacy |

**Explicit note on independence:** External statistical validation (independent cohort) is **not available** — the External summary block reports direction-concordant 0/0, FDR ≤ 0.05 = 0, P ≤ 0.05 = 0. Pathway, Reactome, STRING, and literature sources are contextual evidence; they do not substitute for replication.

## 6. Limitations and Alternative Explanations

1. **Probe-level direction conflicts.** DCBLD2 (mixed direction across probes), LOC101928747|RBMX|SNORD61, and BCL2L14 (mixed across probes) each carry direction-conflict flags. 53 probe duplicates in total indicate that some "genes" may be partly artifacts of probe-set selection. Next step: re-extract and recompute HR at the gene level using a single representative probe or median across concordant probes.

2. **Absence of independent cohort validation.** No external OS statistic was supplied. All claims of "prognostic significance" rest on a single cohort. Pathway co-membership, STRING edges, and literature mentions are not independent replication.

3. **Tumor purity, stromal fraction, and cell-composition effects.** The protective mitochondrial cluster is vulnerable to tumor-purity confounding: high stromal contamination can suppress mitochondrial transcripts. The risk-associated EMT/cytoskeletal module is vulnerable to stromal enrichment bias: mesenchymal cell content elevates TPM4, MAP1B, ITGBL1, NIN regardless of tumor biology. Estimate tumor purity (e.g., ESTIMATE, IHC for α-SMA, vimentin) and stratify or adjust in Cox models.

4. **Treatment exposure and stage not controlled.** Anti-EGFR, anti-VEGF, and chemotherapy exposure may shift both HR direction and magnitude, particularly for the immune/adenosine (NT5E) and PI3K/AKT (AKT3, FGF19) programs. Stage (I–IV) and MSI status are not provided; these can flip CDX2 and LGALS9 directions in published series.

5. **Association-versus-causation ambiguity.** All HRs describe statistical association between transcript level and OS hazard; none demonstrate causality. INHBB risk and CDX2 protection are supported by independent mechanistic literature, but the remaining genes rest on statistical association only. No Mendelian randomization, eQTL, or functional perturbation evidence is present.

### Closing

This signature most plausibly reflects a composite of **(A) retained intestinal differentiation**, **(B) EMT/invasion activation**, **(C) preserved mitochondrial catabolism**, **(D) TGF-β/PI3K stress signaling**, and **(E) immunometabolic/mesothelial surface remodeling**. INHBB, NT5E, CDX2, and the mitochondrial cluster are the most defensible individual anchors with external-literature support, but external-cohort replication is the critical next step before any of these should be promoted to a clinically actionable biomarker or therapeutic target.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=124, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
